| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ECHA InfoCard | 100.055.320 |
| Chemical and physical data | |
| Formula | C12H8BiK5O14 |
| Molar mass | 780.654 g·mol−1 |
| 3D model (JSmol) | |
| |
Bismuth subcitrate potassium is abismuth salt used in combination with antibiotics and aproton pump inhibitor for the treatment ofHelicobacter pylori infections.[1][2]
A fixed-dose combination with the antibioticsmetronidazole andtetracycline is sold under the trade namePylera.[3]
![[icon]](/mt/?noimg=&dark=on&url=http%3a%2f%2fwww.wikipedia.org%2fwiki%2fFile%3aWiki_letter_w_cropped.svg) | This section is empty. You can help byadding to it.(August 2022) |
A known side effect of bismuth salts is harmless and reversible darkening of tongue and stool by formation of bismuthsulfite.[3] Other side effects of bismuth containing combination therapies are often difficult to assign to a specific component.[citation needed]
Bismuth absorption is increased byranitidine andomeprazole.[3]
The mechanism of action of bismuth is not known. It has been reasoned to interfere with the function of the bacterialcell membrane,protein andcell wall synthesis, the enzymeurease,cell adhesion,ATP synthesis, and iron transport mechanisms.[3]
Bismuth subcitrate potassium is a salt ofbismuth (Bi3+),potassium (K+) andcitrate (C6H4O4−7) in amolar ratio of about 1:5:2, with 3 moles of water. It contains about 25.6% (mass percent) bismuth, which is the activemoiety, and 22.9% potassium.[3][4] Other sources give somewhat different ratios of the constituents.